#1 Clinical Trials Search in Europe

Bulevirtide

Bulevirtide is an innovative drug being studied in clinical trials for the treatment of chronic hepatitis D, a serious liver infection caused by the hepatitis D virus (HDV). This article explores the ongoing research into bulevirtide’s effectiveness, safety, and potential to improve outcomes for patients with this challenging condition.

Table of Contents

What is Bulevirtide?

Bulevirtide is a new medication used to treat chronic hepatitis D, which is considered the most severe form of viral hepatitis[4]. It is also known by the brand name Hepcludex® and was previously called Myrcludex B during its development[5]. Bulevirtide received conditional approval from the European Medicines Agency in July 2020, making it the first specific treatment available for chronic hepatitis D[4].

How Does Bulevirtide Work?

Bulevirtide works by blocking the entry of hepatitis B and D viruses into liver cells. It does this by binding to and inactivating a protein called NTCP (Na+-taurocholate cotransporting polypeptide), which normally helps these viruses enter liver cells[1]. By preventing the viruses from entering liver cells, bulevirtide helps to reduce the amount of virus in the body and may slow down or stop liver damage.

What Conditions Does Bulevirtide Treat?

Bulevirtide is specifically approved for the treatment of chronic hepatitis D infection[2]. Hepatitis D is a rare but severe form of viral hepatitis that only occurs in people who are also infected with hepatitis B virus. It can lead to rapid progression of liver disease, increasing the risk of cirrhosis (scarring of the liver) and liver cancer[1].

How is Bulevirtide Administered?

Bulevirtide is given as a daily subcutaneous injection, which means it is injected just under the skin. The typical dose is 2 mg per day[1][4]. Some studies are also investigating a higher dose of 10 mg per day[3]. Patients may need to continue treatment for several months or even years, depending on their response to the medication.

Effectiveness of Bulevirtide

The effectiveness of bulevirtide is measured in several ways:

  • Virological response: This is typically defined as a significant decrease in the amount of hepatitis D virus in the blood (often a decrease of at least 2 log10 IU/mL) or when the virus becomes undetectable[4].
  • Biochemical response: This refers to the normalization of liver enzyme levels, particularly ALT (alanine aminotransferase), which indicates reduced liver inflammation[4].
  • Combined response: This occurs when a patient achieves both a virological and biochemical response[3].

Studies have shown that many patients achieve these responses within 48 weeks of starting treatment, with some maintaining the response even after stopping the medication[3].

Safety and Side Effects

Bulevirtide is generally well-tolerated, but like all medications, it can cause side effects. Common side effects may include:

  • Injection site reactions (such as redness or swelling where the medication is injected)[4]
  • Increases in bile acid levels in the blood[5]

Researchers are closely monitoring for any serious side effects or long-term safety concerns as more patients receive the medication[2].

Ongoing Research

Several clinical trials are currently underway to further study bulevirtide. These studies aim to:

  • Evaluate the long-term effectiveness and safety of bulevirtide[2]
  • Investigate its effects on portal hypertension (high blood pressure in the liver’s blood vessels) in patients with cirrhosis[6]
  • Study how the medication works in patients with different degrees of liver function[5]
  • Explore potential biomarkers that might predict treatment response[4]

These ongoing studies will help doctors better understand how to use bulevirtide effectively and safely in different patient populations.

Aspect Details
Drug Name Bulevirtide (also known as Hepcludex®, Myrcludex B)
Target Condition Chronic Hepatitis D (HDV) infection
Mechanism of Action Blocks virus entry into liver cells by targeting NTCP protein
Administration Daily subcutaneous injection (2 mg or 10 mg)
Primary Outcomes Reduction in HDV RNA levels, ALT normalization
Secondary Outcomes Liver fibrosis improvement, prevention of complications (e.g., HCC)
Treatment Duration Varies by study, often 96-240 weeks
Safety Monitoring Adverse events, laboratory abnormalities, bile acid levels
Patient Populations Adults with chronic HDV, including those with cirrhosis
Ongoing Research Long-term efficacy, real-world effectiveness, immune responses

FAQ

  • What is bulevirtide and how does it work? Bulevirtide is a drug that blocks the entry of hepatitis B and D viruses into liver cells. It does this by binding to and inactivating a protein called NTCP, which the viruses normally use to enter cells.
  • What is the main goal of bulevirtide treatment in clinical trials? The main goal is to reduce levels of HDV RNA in the blood, ideally making it undetectable, and to normalize liver enzyme levels like ALT. This indicates the drug is suppressing the virus and reducing liver inflammation.
  • How is bulevirtide administered? Bulevirtide is given as a daily subcutaneous (under the skin) injection, typically at a dose of 2 mg or 10 mg per day.
  • How long do patients typically take bulevirtide in clinical trials? Treatment duration varies, but many trials are evaluating long-term use of 96 weeks (about 2 years) or longer, with some studies following patients for up to 240 weeks (about 4.5 years).
  • What are some of the key outcomes being measured in bulevirtide trials? Key outcomes include viral response (reduction in HDV RNA levels), normalization of liver enzymes, improvements in liver health measures like fibrosis, and long-term outcomes like preventing liver cancer or liver failure.

Ongoing Clinical Trials on Bulevirtide

  • A study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Czechia France Germany Italy Romania +1

  • Clinical Trial for Patients with Chronic Hepatitis D: Comparing Brelovitug and Bulevirtide Treatments

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Czechia France Germany Italy Romania +2

  • Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection Not Responding to Bulevirtide Treatment

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria France Germany Italy Romania Spain

  • Study on the Effects and Safety of Bulevirtide, Peginterferon Alfa-2a, and Entecavir in Patients with Chronic Hepatitis D

    Recruiting

    1 1 1 1
    Investigated drugs:
    Sweden

  • Study on the Effects of Tobevibart and Elebsiran Compared to Bulevirtide for Patients with Chronic Hepatitis D Virus Infection

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium Bulgaria France Germany Italy The Netherlands +2

  • Study on Bulevirtide Treatment for Patients with Chronic Hepatitis D

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium France Germany The Netherlands Romania +1

Glossary

  • Hepatitis D virus (HDV): A virus that requires the presence of hepatitis B virus to infect liver cells and cause liver disease.
  • Bulevirtide: An antiviral drug that blocks the entry of hepatitis B and D viruses into liver cells by targeting the NTCP protein.
  • HDV RNA: The genetic material of the hepatitis D virus, which is measured in the blood to assess the amount of virus present.
  • ALT (Alanine aminotransferase): A liver enzyme that is measured in the blood. Elevated levels can indicate liver inflammation or damage.
  • Cirrhosis: Severe scarring of the liver, often caused by long-term liver disease.
  • Hepatocellular carcinoma (HCC): The most common type of primary liver cancer.
  • Fibrosis: The formation of scar tissue in the liver, which can occur due to chronic inflammation.
  • Subcutaneous injection: An injection given under the skin.
  • NTCP (Na+-taurocholate cotransporting polypeptide): A protein on liver cells that hepatitis B and D viruses use to enter the cells. Bulevirtide blocks this protein.
  • Virological response: A reduction in the amount of virus in the body, often measured by a decrease in viral RNA levels in the blood.
  • Combined response: In hepatitis D treatment, this typically refers to both a reduction in virus levels and normalization of liver enzymes.

References

  1. https://clinicaltrials.gov/study/NCT05928000
  2. https://clinicaltrials.gov/study/NCT05718700
  3. https://clinicaltrials.gov/study/NCT03852719
  4. https://clinicaltrials.gov/study/NCT06051045
  5. https://clinicaltrials.gov/study/NCT05765344
  6. https://clinicaltrials.gov/study/NCT04863703